On Jul. 2, 2020, the National Medical Product Administration (NMPA) and the National Health Commission (NHC) published the 2020 Edition of the Pharmacopoeia of the People's Republic of China1 (hereinafter referred to as Chinese Pharmacopoeia), which will come into force on Dec. 30, 2020.2
The Chinese Pharmacopoeia is an official legal collection of standards for drug development, production, sales, utilization, supervision, and control in China. The Chinese Pharmacopoeia 2020 Edition is the 11th edition of Chinese Pharmacopoeia, covering 5,911 medicines, including traditional Chinese medicine, chemical drugs, biologics, and pharmaceutical excipients. All finished pharmaceutical products with China's marketing authorization shall meet the technical requirements of dosage forms, test methods, guidelines, etc., in the Chinese Pharmacopoeia since the day of implementation.